H. Lundbeck A/S Class A · OMXCOP:HLUN_A
H. Lundbeck A/S Class A — 9M 2001 Earnings Presentation
18 slides from H. Lundbeck A/S Class A's earnings presentation, November 2001
Slide 1: Interim Report 9M, 2001
H. Lundbeck A/S Interim Report 9M, 2001 November, November, 2001 2001 H. Lundbeck A/S
Slide 2: Safe Harbour Statement
Safe Harbour Statement This presentation contains forward-looking statements that reflect the Management’s current views with respect to certain future events and financial performance. Statements containing the outlook for 2001 and the following years naturally involve uncertainties, and consequent
Slide 3: About Lundbeck
About Lundbeck • H. Lundbeck A/S is... • a unique pharmaceutical company focusing solely on the treatment of diseases of the central nervous system • the third largest pharmaceutical company in Western Europe within antidepressants and sixth largest company within sales of antipsychotics (IMS Health
Slide 4: The new Lundbeck
The new Lundbeck Global Competitive launch sales forces New Lundbeck Multiple New focus products areas H. Lundbeck A/S
Slide 5: Global expansion
Global expansion 1990 2001 Local sales organisation Global sales organisation Lundbeck subsidiaries Lundbeck partner alliance H. Lundbeck A/S 5
Slide 6: Products to be launched
Products to be launched Segment Depression Escitalopram (‘02) Siramesine (‘03+) Anxiety Psychosis* Lu 35-138 (‘03+) Epilepsy Sleep disorders Gaboxadol (‘03+) Migraine Rasagiline (‘03) Parkinson’s CEP 1347 (‘03+) Etilevodopa (‘03) MS Copaxone (‘03) Alzheimer’s Memantine (‘02) Lu 02-659 (‘03+) 2002 20
Slide 7: 9M 2001 - Highlights
9M 2001 - Highlights n Revenue increased by 48% to DKK 5,622 million n Sales of Cipramil increased by 38% to DKK 3,421 million n Income from Celexa sales in the USA increased from DKK 600 million to DKK 1,136 million n Profit from operations increased by 126% to DKK 1,749 million n Profit before tax
Slide 8: Strong revenue growth
Strong revenue growth CAGR 1996 - 2000: 25% 5.6 5.6 (DKKb) 41% 48% 4.0 3.8 3.2 2.6 2.3 1996 1997 1998 1999 2000 9M 9M 2000 2001 Cipramil/Celexa Escitalopram,USA Other Anti-depressants Antipsychotics Other Revenue H. Lundbeck A/S 8
Slide 9: Strong Revenue Growth
Strong Revenue Growth Growth 48% 9M 2000 9M 2001 Canada Canada 6% 4% RoW 11% RoW UK US 9% 10% UK 16% 11% US 24% France France 8% 9% Germany Germany 5% Rest of Europe 8% 37% Spain Spain 3% Rest of Europe Italy 3% 30% Italy 3% 3% H. Lundbeck A/S 9
Slide 10: Growth in major markets
Growth in 7 major markets Cipramil sales* (DKKm) 9M 2001 9M 2000 Change UK 471.3 338.3 39% France 435.0 310.4 40% Germany 191.5 151.9 26% Italy 165.6 107.1 55% Spain 138.2 98.1 41% Australia 129.9 83.8 55% Canada 310.1 145.7 113% 7 big countries 1,841.6 1,235.3 49% % of total sales 33% 32% * Adjuste
Slide 11: Celexa share of new prescriptions in USA
Celexa® ® share of new prescrip. in USA 18% 16% 14% 12% 10% 8% 6% 4% 2% 0% 1 8 15 22 29 36 43 50 57 64 71 78 85 92 99 106 113 120 127 134 141 148 155 162 Launch USA: 09/98 H. Lundbeck A/S 11
Slide 12: Cost and net profit development
Cost and net profit development DKKb Operating Costs Net profit ratio 5,0 4,5 4,0 % 3,5 35 3,0 30 2,5 25 2,0 20 1,5 15 1,0 10 0,5 5 0,0 0 1996 1997 1998 1999 2000 9M 2000 9M 2001 1996 1997 1998 1999 2000 9M 2001 COGS S,G&A R&D H. Lundbeck A/S 12
Slide 13: Cost structure
Cost structure 9M 2001 9M 2000 (DKKm) Production costs 974 793 Distribution costs 1211 891 Administration costs 648 509 Research and development costs 1045 837 H. Lundbeck A/S 13
Slide 14: Cash flow
Cash flow 1558 1153 Capex Cash Flow from Operations 983 981 836 681 646 DKK million 461 407 316 276 267 216 182 1996 1997 1998 1999 2000 9M 2000 9M 2001 H. Lundbeck A/S 14
Slide 15: Cash flow
Cash flow (DKKm) 9M 2001 9M 2000 Cash flow from operating activities 981 646 Cash flow from investing activities - 1,558 - 316 Cash flow from operating and investing activities - 577 330 Cash flow from financing activities - 181 - 96 Increase/decrease in cash and cash equivalents - 758 234 H. Lundbe
Slide 16: Lundbeck pipeline
Lundbeck pipeline Compound Activity Indication 2001 2001 2002 2002 2003 2003 2003+ 2003+ Escitalopram Escitalopram SSRI SSRI Depression Depression NDA Launch Memantine Memantine NMDA NMDAantagonist antagonist Alzheimer’s Alzheimer’s NDA Launch Glatiramer Glatiramer Oral OralCopaxone Copaxone acetate
Slide 17: Q & A
H. Lundbeck A/S Specialist in psychiatry, pioneers in neurology Q&A H. Lundbeck A/S
Slide 18: Key figures
Key figures 9M 2001 9M 2000* Earnings per share - EPS (DKK) 4.44 2.95 Cash flow per share - CFPS (DKK) 4.21 2.77 Net profit ratio (%) 31.1 20.3 Return on assets (%) 43.4 27.4 Return on equity (%) 25.0 21.5 Solvency ratio (%) 63.8 58.9 Net asset value per share (DKK) 19.46 14.88 *) The figures for 9M